Compounds and combinations thereof for treating neurological and psychiatric conditions
Herriot Tabuteau, New York, NY (US)
Assigned to ANTECIP BIOVENTURES II LLC, New York, NY (US)
Filed by ANTECIP BIOVENTURES II LLC, New York, NY (US)
Filed on Apr. 17, 2025, as Appl. No. 19/182,463.
Application 19/182,463 is a continuation of application No. 18/899,500, filed on Sep. 27, 2024, granted, now 12,377,091.
Application 18/899,500 is a continuation of application No. 18/475,841, filed on Sep. 27, 2023, granted, now 12,138,260, issued on Nov. 12, 2024.
Application 18/475,841 is a continuation of application No. 17/929,147, filed on Sep. 1, 2022, granted, now 11,779,579, issued on Oct. 10, 2023.
Application 17/929,147 is a continuation of application No. 17/547,050, filed on Dec. 9, 2021, granted, now 11,433,067, issued on Sep. 6, 2022.
Application 17/547,050 is a continuation in part of application No. 17/066,310, filed on Oct. 8, 2020, granted, now 11,229,640, issued on Jan. 25, 2022.
Application 17/066,310 is a continuation in part of application No. 16/894,713, filed on Jun. 5, 2020, granted, now 10,898,453, issued on Jan. 26, 2021.
Prior Publication US 2025/0241907 A1, Jul. 31, 2025
1. A method of treating agitation associated with Alzheimer's disease in a human being suffering from agitation associated with Alzheimer's disease; comprising orally administering a first tablet once daily for one week followed by twice daily for one week, then a second tablet twice daily to the human being; wherein the first tablet contains about 105 mg of bupropion hydrochloride or a molar equivalent amount of another salt form of bupropion or the free base form of bupropion, and about 30 mg of dextromethorphan hydrobromide or a molar equivalent amount of another salt form of dextromethorphan or the free base form of dextromethorphan; and the second tablet contains about 105 mg of bupropion hydrochloride or a molar equivalent amount of another salt form of bupropion or the free base form of bupropion, and about 45 mg of dextromethorphan hydrobromide or a molar equivalent amount of another salt form of dextromethorphan or the free base form of dextromethorphan; wherein the dextromethorphan and the bupropion are the only therapeutically active agents in the first or second tablet; and wherein the human being is an extensive metabolizer of dextromethorphan.